Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

62.90
+0.66001.06%
Pre-market: 64.001.10+1.75%06:25 EDT
Volume:1.20M
Turnover:75.27M
Market Cap:6.64B
PE:51.14
High:64.26
Open:62.06
Low:61.75
Close:62.24
Loading ...

Equity Markets Mixed Ahead of Tariff Announcements

MT Newswires Live
·
01 Apr

Why Is Corcept (CORT) Stock Soaring Today

StockStory
·
01 Apr

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

Simply Wall St.
·
01 Apr

Top Midday Gainers

MT Newswires Live
·
01 Apr

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 Apr

Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating

MT Newswires Live
·
31 Mar

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet

Benzinga
·
31 Mar

Corcept Therapeutics price target raised to $128 from $78 at Piper Sandler

TIPRANKS
·
31 Mar

Truist Securities Adjusts Corcept Therapeutics Price Target to $150 From $76, Maintains Buy Rating

MT Newswires Live
·
31 Mar

BUZZ-Corcept hits record high as ovarian cancer drug succeeds late-stage trial

Reuters
·
31 Mar

Corcept Therapeutics Inc : Truist Securities Raises Target Price to $150 From $76

THOMSON REUTERS
·
31 Mar

HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating

MT Newswires Live
·
31 Mar

Corcept Therapeutics price target raised to $150 from $115 at H.C. Wainwright

TIPRANKS
·
31 Mar

Corcept Therapeutics Inc. : H.c. Wainwright Raises Target Price to $150 From $115

THOMSON REUTERS
·
31 Mar

Corcept Soars as Ovarian Cancer Drug Succeeds Late-Stage Trial

Reuters
·
31 Mar

Corcept Therapeutics Jumps 84% After Co's Ovarian Cancer Combo Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
31 Mar

Sector Update: Health Care

MT Newswires Live
·
31 Mar

Corcept Therapeutics Shares Soar on Positive Ovarian Cancer Treatment Trial Results

Dow Jones
·
31 Mar

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

MT Newswires Live
·
31 Mar

Corcept Therapeutics Jumps 83% Premarket After Co's Ovarian Cancer Combination Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
31 Mar